This sounds very helpful.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=159422&CultureCode=en
This activator has proved a capacity to generate an important
increase in neurogenesis and represents a first step for future medicine
for patients suffering from certain neurology diseases
Many neurology pathologies cause irreversible loss of neurons. They
are mostly the so-called neurodegenerative diseases although there exist
other causes for a focal loss of neurons, as it is the case in strokes
or traumatic brain injuries. All these pathologies lack nowadays of an
efficient treatment not being possible to regenerate dead neurons. In
fact, although the brain has the ability to regenerate as many studies
has proved, this regeneration is very low, ranging from 0.2% to a
maximum of 10% depending on the type of injury and the damaged area.
This is why different research groups have focused their activities
in achieving regeneration of a brain area suffering from neuronal cell
death so that this area can recover its function. For years, the team
led by Professor Carmen Castro at the University of Cadiz work on this
line. One of the latest progress of their research will be soon
published in the International Journal of Neuropsychopharmacology under
the title “12-Deoxyphorbols Promote Adult Neurogenesis by Inducing
Neural Progenitor Cell Proliferation via PKC Activation”, which is
already available on an online version. In this article fully
subscribed by UCA researchers including a researchers group from the
Department of Organic Chemistry led by Dr Rosario Hernandez, it is
proved how a number of isolated plant natural products with the ability
to activate a family of proteins known as Kinase c type or PKC
facilitates proliferation of neuronal cells in the brain. The research
group has patented the use of these compounds to regenerate the nervous
system.
“There exist other compounds in the market activating this family of
proteins but they imply a high level of tumorigenesis. They could not
be actually used as a regenerative therapy so we searched for other
activators achieving an increase in neurogenesis without a tumorigenesis
effect”, Dr Carmen Castro states. Having this in mind, “we got in
contact with a research group from the Department of Organic Chemistry
working on the isolation of natural products out of plants and having
compounds of the family of the 12 deoxyphorbols. This group had
published that some of these compounds were able to activate PKC and
that they did not imply tumorigenesis. This is why we decided to
cooperate with them and prove these compounds, at a first stage, on
cultures and later on, on mice”.
Thus, the UCA researchers could check how these compounds facilitate
proliferation in neuronal precursor cells cultures and that their
introduction in an adult mouse brain favours the generation of new
neuronal cells.
Moreover, “nowadays we are studying other less invasive routes of
administration of this compound rather than injecting medication
directly into the brain. This type of compounds are difficult to obtain
so that a way to administer a little quantity has to be found. It is
also necessary that the whole quantity gets to the brain as if they are
injected into blood, final quantity into the brain will be very little”,
as they explain from the UCA.
The work done so far is a first stage of a much more complex project
with a final objective of developing new medicines in the long term.
However, these researchers come to highlight that “it has not been easy
to arrive up to this point. This work has demanded a great effort on the
side of the staff of this institution as we are going through a period
with great difficulties to obtain funding”.
http://ijnp.oxfordjournals.org/content/ijnp/early/2015/08/13/ijnp.pyv085.full.pdf
No comments:
Post a Comment